سامانه مدیریت نشریات علمی دانشگاه علوم پزشکی مشهد

Ashrafpour, Ramin, Ayati, Narjess, Sadeghi, Ramin, Zare Namdar, Samira, Ayati, Nayyereh, Ghahremani, Somaye, Zakavi, Seyed Rasoul. (1397). Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer. , 6(2), 108-112. doi: 10.22038/aojnmb.2018.26793.1187
Ramin Ashrafpour; Narjess Ayati; Ramin Sadeghi; Samira Zare Namdar; Nayyereh Ayati; Somaye Ghahremani; Seyed Rasoul Zakavi. "Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer". , 6, 2, 1397, 108-112. doi: 10.22038/aojnmb.2018.26793.1187
Ashrafpour, Ramin, Ayati, Narjess, Sadeghi, Ramin, Zare Namdar, Samira, Ayati, Nayyereh, Ghahremani, Somaye, Zakavi, Seyed Rasoul. (1397). 'Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer', , 6(2), pp. 108-112. doi: 10.22038/aojnmb.2018.26793.1187
Ashrafpour, Ramin, Ayati, Narjess, Sadeghi, Ramin, Zare Namdar, Samira, Ayati, Nayyereh, Ghahremani, Somaye, Zakavi, Seyed Rasoul. Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer. , 1397; 6(2): 108-112. doi: 10.22038/aojnmb.2018.26793.1187

Comparison of Treatment Response Achieved by Tablet Splitting Versus Whole Tablet Administration of Levothyroxine in Patients with Thyroid Cancer

Asia Oceania Journal of Nuclear Medicine and Biology
مقاله 4، دوره 6، شماره 2، مهر 2018، صفحه 108-112    اصل مقاله (420.58 K)
نوع مقاله: Original Article
شناسه دیجیتال (DOI): 10.22038/aojnmb.2018.26793.1187
نویسندگان
Ramin Ashrafpour1؛ Narjess Ayati* 2؛ Ramin Sadeghi3؛ Samira Zare Namdar3؛ Nayyereh Ayati4؛ Somaye Ghahremani5؛ Seyed Rasoul Zakavi6
1School of medicine, Mashhad University of Medical Sciences, Mashhad, Iran
2Nuclear Medicine Research Center, Mashhad University of Medical Science
3Nuclear Medicine Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
4Department of pharmacoeconomics and pharmaceutical administration, faculty of pharmacy, Tehran University of medical sciences, Tehran, Iran
5nuclear medicine research center, ghaem hospital,mashhad,iran
6Nuclear Medicine Research Center, Mashhad University of Medical Sciences
چکیده
Objective(s): TSH suppression by Levothyroxine consumption is a mainstay of thyroid cancer treatment. Tablet-splitting is a worldwide approach in dose adjustment in patients. However, it is highly recommended to evaluate the validity of tablet splitting for each distinctive drug by clinical trials before routinely using tablet halves in clinical practice. In this study we compared the effect of 150 μg dose of Levothyroxine by use of a100 and a 50 μg tablets or one and half 100 μg tablets in Differentiated thyroid cancer (DTC) patients.
Methods: One hundred DTC patients treated with one and half 100 μg Levothyroxine tablets were randomly divided into two groups. The first group continued taking medication as before and the second group received the same daily dose by taking one 100 and one 50 microgram Levothyroxine tablets. The mean changes in TSH and T3 levels and patients weight were compared between the groups.
Results: 91 patients completed the study. Levothyroxine consumption pattern, age, gender distribution, weight and TSH levels were comparable between groups at the beginning of the study. The mean change of body weights, serum levels of T3 and TSH showed no significant difference between groups in different time points during the study (P>0.05).
Conclusion: This study showed similar efficacy of tablet splitting and two tablets administration for Levothyroxine; however, patients preferred two tablets at the end of the study. It can be concluded that tablet splitting can be used as an alternative way when the 50 μg tablet is not available.
کلیدواژه‌ها
Tablet splitting؛ Differentiated thyroid cancer, TSH, Levothyroxine, suppressive therapy
مراجع
  1. Zakavi SR, Ayati N, Farahati J, Davachi B. Diffuse skeletal metastasis and low thyroglobulin level in a pediatric patient with papillary thyroid carcinoma. Indian J Nucl Med. 2015;30(3):283-5.
  2. Zakavi SR. Meta-analysis on successful ablation after low- versus high-dose radioiodine therapy in patients with differentiated thyroid carcinoma. Clin Nucl Med. 2016;41(8):674.
  3. Haugen BR. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: what is new and what has changed? Cancer. 2017; 123(3):372-81.
  4. Freeman MK, White W, Iranikhah M. Tablet splitting: a review of the clinical and economic outcomes and patient acceptance. Second of a 2-part series. Part 1 was published in May 2012 (Consult Pharm 2012;27:239-53). Consult Pharm. 2012;27(6):421-30.
  5. Elliott I, Mayxay M, Yeuichaixong S, Lee SJ, Newton PN. The practice and clinical implications of tablet splitting in international health. Trop Med Int Health. 2014; 19(7):754-60.
  6. Verrue C, Mehuys E, Boussery K, Remon JP, Petrovic M. Tablet-splitting: a common yet not so innocent practice. J Adv Nurs. 2011;67(1):26-32.
  7. Tablet splitting. JAMA. 2014;311(5):521.
  8. Chou CL, Hsu CC, Chou CY, Chen TJ, Chou LF, Chou YC. Tablet splitting of narrow therapeutic index drugs: a nationwide survey in Taiwan. Int J Clin Pharm. 2015;37(6):1235-41.
  9. Tahaineh LM, Gharaibeh SF. Tablet splitting and weight uniformity of half-tablets of 4 medications in pharmacy practice. J Pharm Pract. 2012;25(4):471-6.
10. Dormuth CR, Schneeweiss S, Brookhart AM, Carney G, Bassett K, Adams S, et al. Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis. Open Med. 2008;2(3):e74-82.

11. Vranic E, Uzunovic A. Influence of tablet splitting on content uniformity of lisinopril/hydrochlorthiazide tablets. Bosn J Basic Med Sci. 2007;7(4):328-34.

12. Cook TJ, Edwards S, Gyemah C, Shah M, Shah I, Fox T. Variability in tablet fragment weights when splitting unscored cyclobenzaprine 10 mg tablets. J Am Pharm Assoc. 2004;44(5):583-6.

13. Zhao N, Zidan A, Tawakkul M, Sayeed VA, Khan M. Tablet splitting: product quality assessment of metoprolol succinate extended release tablets. Int J Pharm. 2010;401(1-2):25-31.

14. Nidanapu RP, Rajan S, Mahadevan S, Gitanjali B. Tablet splitting of antiepileptic drugs in pediatric epilepsy: potential effect on plasma drug concentrations. Paediatr Drugs. 2016;18(6):451-63.

15. Abu-Geras D, Hadziomerovic D, Leau A, Khan RN, Gudka S, Locher C, et al. Accuracy of tablet splitting and liquid measurements: an examination of who, what and how. J Pharm Pharmacol. 2017;69(5):603-12.

16. Mascarenhas Starling F, Medeiros-Souza P, Francisco de Camargos E, Ferreira F, Rodrigues Silva A, Homem-de-Mello M. Tablet splitting of psychotropic drugs for patients with dementia: a pharmacoepidemiologic study in a Brazilian sample. Clin Ther. 2015;37(10):2332-8.

17. Quinzler R, Gasse C, Schneider A, Kaufmann-Kolle P, Szecsenyi J, Haefeli WE. The frequency of inappropriate tablet splitting in primary care. Eur J Clin Pharmacol. 2006;62(12):1065-73.

18. Tablet splitting: evaluating appropriateness for patients. J Am Pharm Assoc. 2004;44(3):324-5.

19. Peek BT, Al-Achi A, Coombs SJ. Accuracy of tablet splitting by elderly patients. JAMA. 2002;288(4): 451-2.

20. Shah RB, Collier JS, Sayeed VA, Bryant A, Habib MJ, Khan MA. Tablet splitting of a narrow therapeutic index drug: a case with levothyroxine sodium. AAPS PharmSciTech. 2010;11(3):1359-67.

21. Helmy SA. Tablet splitting: is it worthwhile? Analysis of drug content and weight uniformity for half tablets of 16 commonly used medications in the outpatient setting. J Manag Care Spec Pharm. 2015;21(1):76-86.

22. Freeman MK, White W, Iranikhah M. Tablet splitting: a review of weight and content uniformity. Consult Pharm. 2012;27(5):341-52.

23. McDevitt JT, Gurst AH, Chen Y. Accuracy of tablet splitting. Pharmacotherapy. 1998;18(1):193-7.

24. Zakavi SR, Zare NS, Shafiei S, Sadeghi R, Fekri N, Mazloum KZ, et al. Which complaint has the most clinical effect on quality of life of thyroid cancer survivors in long term follow up? Iran J Nucl Med. 2015;23(1):21-6.

25. Vuchetich PJ, Garis RI, Jorgensen AM. Evaluation of cost savings to a state Medicaid program following a sertraline tablet-splitting program. J Am Pharm Assoc. 2003;43(4):497-502.

26. Curtiss FR. Tablet splitting to improve the value-for-money equation in cholesterol management. J Manag Care Pharm. 2002;8(6):519.

27. Fawell NG, Cookson TL, Scranton SS. Relationship between tablet splitting and compliance, drug acquisition cost, and patient acceptance. Am J Health Syst Pharm. 1999;56(24):2542-5.

آمار
تعداد مشاهده مقاله: 2,063
تعداد دریافت فایل اصل مقاله: 641